Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
The U.S. Food and Drug Administration (FDA) has expanded the number of cystic fibrosis (CF)-related mutations considered responsive to and therefore eligible for Vertex Pharmaceuticals‘ three approved therapies. With these ... Read more
The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to ... Read more
The Australian Medical Services Advisory Committee (MSAC) has recommended that the costs of screening for mutations known to cause cystic fibrosis (CF), spinal muscular atrophy (SMA), and fragile X syndrome ... Read more
A Phase 1b clinical trial evaluating Calithera Biosciences’ investigational oral therapy CB-280 is recruiting adults with cystic fibrosis (CF) and chronic airway infections at several U.S. sites. The trial’s ... Read more
The frequency of nontuberculous mycobacteria (NTM) infections in children and adolescents with cystic fibrosis (CF) in the U.K. remained stable from 2016 to 2018, but substantially higher than at ... Read more
Nonprofit Emily’s Entourage has awarded a total of $790,000 to four research projects focused on potential therapies for cystic fibrosis (CF) and related lung infections. To be given over ... Read more